Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.
about
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for the long term treatment of venous thromboembolism in patients with cancerAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesManagement of Venous Thromboembolisms: Part I. The Consensus for Deep Vein ThrombosisRecurrent venous thromboembolism: what is the risk and how to prevent itPredicting the risk of venous thromboembolism recurrenceThe epidemiology of venous thromboembolismIncidence and cost burden of post-thrombotic syndromeGuidelines on oral anticoagulation with warfarin - fourth editionA Novel Prioritization Method in Identifying Recurrent Venous Thromboembolism-Related GenesThe postthrombotic syndrome: current evidence and future challenges.Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2)Five-year follow-up of pulmonary embolism under anticoaugulation: The PISA-PEET (Pulmonary Embolism Extension Therapy) studyCurrent treatment of venous thromboembolismIncidence of acute pulmonary embolism, related comorbidities and survival; analysis of a Swedish national cohort.The epidemiology of venous thromboembolism in the community.Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women.Venous and arterial thrombosis: Two aspects of the same disease?Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH.Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol.Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis.Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case-control study.Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: a nested case-control study.The post-thrombotic syndrome: progress and pitfalls.Post-thrombotic syndrome: prevention is better than cure.Fluctuation of serum sodium and its impact on short and long-term mortality following acute pulmonary embolismIs there a Link Between Atherothrombosis and Deep Venous Thrombosis?Utilization of parenteral anticoagulants and warfarin: impact on the risk of venous thromboembolism recurrence in the outpatient setting.The Saudi clinical practice guideline for the diagnosis of the first deep venous thrombosis of the lower extremity.Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysisVenous thromboembolism in patients with reduced estimated GFR: a population-based perspectiveAnticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.Evaluating the Role of Compression Stockings in Preventing Post thrombotic Syndrome: A Review of the Literature.Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disordersCan venous thromboembolism navigate the prevention of cardiovascular complications?Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.The effects of obesity on venous thromboembolism: A review.The predictive factors of recurrent deep vein thrombosis.
P2860
Q24194904-C6384D04-AD6B-4E76-B65D-ADAEAB9038C9Q24236620-7338109A-9B7C-42BD-8067-D4D6CF340FD7Q24243286-A7BD7A0E-935B-4882-A2FB-604525D4919DQ24633053-E55AB293-21D3-401F-BC15-29DD98387B32Q26749273-25AD2797-0705-4086-B934-39C63EDD4830Q26826847-EBC76B27-C65B-4757-92FD-2AB9F83C0A82Q26865059-438CB57C-30C4-4997-B23D-7A1B19CF2778Q28067893-F62E5E69-634C-4D00-9B1B-993757C31A37Q28235459-284330DE-F208-48C5-AA1D-F4830AD1533DQ28240666-61CA9973-F0DE-4778-965E-50B8C9B3964AQ28551214-A743F82C-7E6E-4CF3-A1BB-4C95815B42D7Q30241064-DBBED708-3F5E-4C0B-AB0E-6F3DCA617910Q33587638-2B3EE8A1-19C1-45BF-95F1-B793B4A6FEE6Q33590496-0A13E9F7-2BB0-4E2C-A080-BADCEDF795A0Q33736629-7305BCD3-3F27-4AAC-B7A6-77236E33FC28Q33801396-BB4FFBE1-02A7-4827-AA94-1E88874DBA67Q33865646-7D8B1EE0-04CF-4730-9057-0ED0A4EF057CQ34032280-C24668B8-2EAF-4B02-AE2A-DB472F845ECAQ34143995-C13DD723-1FC2-4074-BCB0-2897AE1B1255Q34254243-59CE3EC8-A9B9-4B15-8545-6930D6500471Q34286102-E7B1FA11-7D95-41A8-BCF8-741C5E1D97E3Q34333548-D77413F4-4C6B-4FE9-B7FC-09D9BAD53C53Q34345802-DA312A61-5589-42AC-B236-FC4690637AD0Q34365575-54B15B96-E34E-47ED-8A5C-8870FF6C0F8FQ34544918-9072920E-797F-428B-814F-0F461C651FEFQ34623824-9A5F6471-343D-441D-90BF-057D3745F60CQ34689321-D9B21799-F14A-4CC8-9B39-F60E4C6E463DQ34717291-87760243-B9B9-40DE-821F-5E02CEEDE9AFQ34792469-77E5197F-EA84-4238-8310-6DFF301DB8C0Q34866266-2B46E7D0-CE08-41A0-B4C4-46ACCBA1EA83Q35067214-E8B43A2D-F5EF-4EEC-97E3-6CD42B0A57C1Q35479128-BBE81E4A-F6B7-4B95-8A60-B2D26D535086Q35724847-468F70E2-5427-47AB-A8DD-5E53486FB805Q35725647-CA2E1A55-5CBE-475D-AAA5-456C894CEB12Q35730774-8D788403-6550-4456-A87E-CDEC9F6577B5Q35739671-F4836B71-7682-4E41-A2A3-7BA7AAA54507Q35783633-9F65D473-589B-418A-A0BF-6203740543ACQ35825548-A56B5C97-5481-4776-9D2E-780AD6FD3BA6Q35904699-5ADC59E8-6A0E-4519-9ACE-C54C542BD496Q35945318-6FC339FA-8BE1-41BC-AD18-624601DE4BB3
P2860
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Post-thrombotic syndrome, recu ...... farin for 6 weeks or 6 months.
@en
Post-thrombotic syndrome, recu ...... farin for 6 weeks or 6 months.
@nl
type
label
Post-thrombotic syndrome, recu ...... farin for 6 weeks or 6 months.
@en
Post-thrombotic syndrome, recu ...... farin for 6 weeks or 6 months.
@nl
prefLabel
Post-thrombotic syndrome, recu ...... farin for 6 weeks or 6 months.
@en
Post-thrombotic syndrome, recu ...... farin for 6 weeks or 6 months.
@nl
P2093
P2860
P1476
Post-thrombotic syndrome, recu ...... farin for 6 weeks or 6 months.
@en
P2093
Carlsson A
Holmström M
Lindmarker P
Ljungberg B
P2860
P304
P356
10.1111/J.1538-7836.2006.01795.X
P50
P577
2006-04-01T00:00:00Z